Scarica l'app Stockscreener
9.01
11.10%
0.90
Dopo l'orario di chiusura:
9.01
Regenxbio Inc Borsa (RGNX) Ultime notizie
DMD Plans Remain Central For Regenxbio Despite Hunter Syndrome FDA Approval Delay - insights.citeline.com
Delay hits Regenxbio BLA review - The Pharma Letter
Regenxbio says FDA extends review date for Hunter syndrome drug - MSN
FDA Extends Review Period for REGENXBIO Hunter Syndrome Treatment - BioPharm International
What recovery options are there for REGENXBIO Inc.July 2025 Intraday Action & Long-Term Investment Growth Plans - Newser
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year - Benzinga
FDA delays decision on Regenxbio gene therapy - statnews.com
Can trapped investors hope for a rebound in REGENXBIO Inc.Market Volume Summary & Stepwise Entry/Exit Trade Alerts - Newser
Regenxbio stock steady as FDA extends RGX-121 review timeline - Investing.com
Regenxbio Inc. shares rise 1.49% premarket after FDA review extension for RGX-121. - AInvest
Regenxbio stock holds steady as FDA extends review of Hunter syndrome gene therapy - Investing.com
FDA extends review of REGENXBIO’s Hunter syndrome therapy - Investing.com
FDA extends review of REGENXBIO’s Hunter syndrome therapy By Investing.com - Investing.com Nigeria
Regenxbio Says FDA Extends Review Timeline for RGX-121 - MarketScreener
Regenxbio's FDA Review Extension for RGX-121 and Its Implications for Gene Therapy Commercialization - AInvest
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II - Citizen Tribune
FDA Extends Review for RegenXBio’s RGX-121 Therapy - TipRanks
FDA delays decision on Regenxbio’s Hunter syndrome gene therapy by three months - Endpoints News
REGENXBIO Inc. Facing Inflection Point in Trend AnalysisJuly 2025 WrapUp & Verified High Yield Trade Plans - kangso.co.kr
Is a relief rally coming for REGENXBIO Inc. holdersMarket Sentiment Summary & Reliable Price Action Trade Plans - Newser
How REGENXBIO Inc. stock performs during market volatility2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Will breakout in REGENXBIO Inc. lead to full recovery2025 AllTime Highs & Verified Momentum Stock Alerts - Newser
What candlestick patterns are forming on REGENXBIO Inc.July 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
Using data tools to time your REGENXBIO Inc. exitMarket Rally & Daily Stock Trend Watchlist - Newser
Can REGENXBIO Inc. hit a new high this month2025 Major Catalysts & Fast Gain Swing Trade Alerts - Newser
Trendline Breach Raises Concern for REGENXBIO Inc. Investors2025 Price Action Summary & Safe Capital Growth Tips - sundaytimes.kr
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛
Technical analysis overview for REGENXBIO Inc. stock2025 Winners & Losers & Detailed Earnings Play Strategies - Newser
Detecting price anomalies in REGENXBIO Inc. with AIJuly 2025 Movers & Real-Time Volume Analysis - Newser
Can REGENXBIO Inc. rally from current levelsJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser
REGENXBIO’s SWOT analysis: gene therapy pioneer’s stock faces pivotal year - Investing.com Canada
When is the best time to exit REGENXBIO Inc.Weekly Trade Recap & High Accuracy Investment Entry Signals - Newser
What makes REGENXBIO Inc. stock price move sharplyMarket Growth Review & Free Weekly Chart Analysis and Trade Guides - thegnnews.com
Are Options Traders Betting on a Big Move in Regenxbio Stock? - Yahoo Finance
What’s next for REGENXBIO Inc. stock priceFree Market Entry and Exit Point Tips - Newser
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel - simplywall.st
XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO (NASDAQ:RGNX) Cut to “Strong Sell” at Wall Street Zen - Defense World
Dystrophin Gene Therapy Market 2025 | $12B Growth, REGENXBIO & - openPR.com
Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com
Royal Bank Of Canada Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - Defense World
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance
REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser
REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World
REGENXBIO Reports Q2 2025 Financial Results and Progress - The Globe and Mail
Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN
Raymond James Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
Regenxbio: RBC Capital Maintains Outperform, PT Down to $17 from $21 - AInvest
Regenxbio price target lowered to $17 from $21 at RBC Capital - TipRanks
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results - Investing.com
RBC Capital lowers Regenxbio stock price target to $17 on quarterly results By Investing.com - Investing.com South Africa
Regenxbio's Q2 2025: Key Contradictions on RGX-121 Approval, Manufacturing Plans, and Pivotal Study Design - AInvest
REGENXBIO Inc. (RGNX): Navigating Q2 2025 Challenges with a High-Stakes Gene Therapy Pipeline - AInvest
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):